Table 2.
Endocrine IRAE in patients treated with tremelimumab
| Study | Cohort Characteristics | Endocrinopathy | ||||||
|---|---|---|---|---|---|---|---|---|
| Avg (range) | n | Hypophysitis | Adrenal insufficiency | Hypothyroidism | Hyperthyroidism | Thyroiditis | Other thyroid# | |
| Ribas et al (2005)68 | 54 (30–78) | 39 | 1 | NR | 1ǂ | 1 | 1 | NR |
| Camacho et al (2009)69 | 54–61 (20–83) | 90 | NR | NR | NR | NR | 1 | 1 |
| Ralph et al (2010)70 | 55.4 (37–75) | 18 | NR | NR | NR | NR | NR | NR |
| Kirkwood et al (2010)71 | 53 (18–89) | 246 | 1 | NR | NR | NR | NR | 8 |
| Chung et al (2010)44 | 62 (39–79) | 47 | NR | NR | 1ǂ | NR | NR | NR |
| Ribas et al (2013)43 | 57 (22–90) | 328 | 6 | 4ǂ | NR | NR | NR | 17 |
| Total | 773 | 8 (1.3%) | 4 (1.2%) | 2 (2.3%) | 1 (2.6%) | 2 (1.6%) | 26 (3.9%) | |
| Events/total§ | 8/613 | 4/328 | 2/86 | 1/39 | 2/129 | 26/664 | ||
#
Includes Grave’s disease, autoimmune thyroiditis and unspecified thyroid disorders.
ǂ
Unspecified cause.
§
Percentage determined by total number of events divided from total number of patients only from studies reporting event.
NR, non reported; IRAE, immune-related adverse events.